CONFIDENTIAL TREATMENT REQUESTED. OMITTED PORTIONS ARE MARKED WITH [*****] AND HAVE BEEN FILED SEPARATELY WITH THE SEC. CROSS-LICENSE AGREEMENT

Exhibit 10.2

CONFIDENTIAL TREATMENT REQUESTED. OMITTED PORTIONS ARE MARKED WITH [*****] AND HAVE BEEN FILED SEPARATELY WITH THE SEC.

This Cross-License Agreement is made by and between OncoSec Medical Incorporated (“ONCSD”), a Nevada corporation, with its principal place of business at 8th Floor - 000 Xxxxxxxx Xxxxxx, Xxxx XX 00000, and Inovio Pharmaceuticals, Inc. (“INO”), a Delaware corporation, with its principal place of business at 0000 Xxxxxx Xxxxxxx West, Building 18, Xxxxx 000, Xxxx Xxxx, XX 00000.

WHEREAS, ONCSD owns or controls certain intellectual property related to electroporation facilitated delivery of chemotherapeutic agents, or nucleic acids encoding cytokines for use as active agent only, into tumors and/or surrounding tissue (or tumor margin tissue) in humans for the treatment and diagnosis of benign and malignant tumors, and wishes to provide a license thereunder to INO;

WHEREAS, INO owns or controls certain intellectual property related to various electroporation devices and their use, and wishes to provide a license thereunder to ONCSD; and

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, the parties hereby agree as follows:

1. DEFINITIONS

1.1 AFFILIATE means any corporation, firm, limited liability company, partnership, or other entity that directly or indirectly controls, or is controlled by, or is under common control with a Party to this AGREEMENT. For the purpose of this definition, “control” means ownership, directly or through one or more AFFILIATES, of fifty percent (50%) (or such lesser percentage which is the maximum allowed to be owned by a foreign entity in a particular jurisdiction) or more of the shares of stock entitled to vote for the election of directors in the case of a corporation, or fifty percent (50%) (or such lesser percentage which is the maximum allowed to be owned by a foreign entity in a particular jurisdiction) or more of the equity interests in the case of any other type of legal entity, or status as a general partner in any partnership, or any other arrangement whereby a Party controls or has the right to control the board of directors or equivalent governing body of a corporation or other entity.

1.2 AGREEMENT means this Cross-License Agreement made by and between OncoSec Medical Incorporated (“ONCSD”) and Inovio Pharmaceuticals, Inc. (INO), including any recitals and Schedules to this agreement, as amended, supplemented or restated from time to time.

1.3 EFFECTIVE DATE means the date on which ONCSD and INO have both fully executed this AGREEMENT.

1.4 EXCLUDED PROCEEDS means all proceeds reasonably and fairly attributable to bona fide [*****]

CONFIDENTIAL TREATMENT REQUESTED. OMITTED PORTIONS ARE MARKED WITH [*****] AND HAVE BEEN FILED SEPARATELY WITH THE SEC.

[*****]

1.5 FAIR MARKET VALUE means the cash consideration which ONCSD or a sublicensee thereof would realize from an unaffiliated, unrelated buyer in an arm’s length sale of an identical item sold in the same quantity and at the same time and place of the transaction.

1.6 INO FIELD means the use of electroporation to deliver genes and/or nucleic acids, outside of those encoding cytokines as active agent only.

1.7 INO PATENT RIGHTS means the rights conferred by the patents listed in Appendix B, including rights to any continuation, continuation-in-part, divisional, renewal, reissue, reexamination, derivative, and foreign counterpart patents thereof.

1.8 NET SALES means the gross amount invoiced for SALES, less qualifying costs directly attributable to such SALES and actually identified on the invoice and borne by ONCSD or its sublicensee(s). Such qualifying costs shall be limited to the following:

1.8.1 [*****]

1.8.2 [*****]

1.8.3 [*****]

1.8.4 [*****]

1.8.5 [*****]

For clarity, NET SALES shall specifically exclude all EXCLUDED PROCEEDS.

1.9 ONCSD FIELD means the use of electroporation to facilitate delivery of chemotherapeutic agents, or nucleic acids encoding cytokines for use as active agent only, into tumors and/or surrounding tissue (or tumor margin tissue) in humans for the treatment and diagnosis of benign and malignant tumors.

1.10 ONCSD PATENT RIGHTS means the rights conferred by the patents listed in Appendix A, including rights to any continuation, continuation-in-part, divisional, renewal, reissue, reexamination, derivative, and foreign counterpart patents thereof.

CONFIDENTIAL TREATMENT REQUESTED. OMITTED PORTIONS ARE MARKED WITH [*****] AND HAVE BEEN FILED SEPARATELY WITH THE SEC.

1.11 PATENTS mean any U.S. and foreign patents, patent applications, and provisional patent applications; U.S. and foreign patents issued from such applications and from any divisional, continuations, or continuations-in-part; reexamination, derivative, and any renewals or reissues thereof.

1.12 SALE means any bona fide transaction for which consideration is received or promised for the sale, use, lease, transfer or other disposition of SECTA TECHNOLOGY to an unrelated third party. A SALE of SECTA TECHNOLOGY shall be deemed completed at the time ONCSD or its sublicensee receives payment for such SECTA TECHNOLOGY.

1.13 SECTA shall mean electroporation facilitated delivery of chemotherapeutic agents, or nucleic acids encoding cytokines for use as active agent only, into tumors and/or surrounding tissue (or tumor margin tissue) in humans for the treatment and diagnosis of benign and malignant tumors.

1.14 SECTA BUSINESS shall mean:

1.14.1 any products or services that are made or designed from or with the aid of the SECTA Technology; or

uses of the SECTA Technology.

1.15 SECTA TECHNOLOGY means all SECTA related technologies, inventions, arts, processes, business methods, developments, patent rights, know-how, registrations, applications for registration, data, information (financial or otherwise), products, devices, documentation, engineering and quality documentation, moulds, machinery, diagrams, and inventory and other intellectual, industrial, tangible or intangible property relating primarily to the Field of Use, whether or not patented or the subject of a patent application, including all trademarks, brands and know-how.

2. LICENSE GRANT

2.1 ONCSD hereby grants to INO a fully paid up, exclusive, worldwide license in the INO FIELD under the ONCSD PATENT RIGHTS (the “ONCSD LICENSE”).

2.2 INO hereby grants to ONCSD a non-exclusive, worldwide license in the ONCSD FIELD under the INO PATENT RIGHTS (the “INO LICENSE”).

3. FEES AND ROYALTIES

3.1 Fees

3.1.1 INO Fees

3.1.1.1 For avoidance of doubt, INO does not owe ONCSD any upfront fees [*****] in exchange for the ONCSD LICENSE.

CONFIDENTIAL TREATMENT REQUESTED. OMITTED PORTIONS ARE MARKED WITH [*****] AND HAVE BEEN FILED SEPARATELY WITH THE SEC.

3.1.1.2 ONCSD Fees

3.1.1.3 For avoidance of doubt, ONCSD does not owe any upfront fees [*****] in exchange for the INO LICENSE.

3.1.1.4 ONSC shall pay to INO [*****] of any fee or payment in cash or equity that ONSC receives in return for a sublicense to a third party of the INO PATENT RIGHTS, but excludes any amounts received by ONSC as a form of investment or financing.

3.1.1.5 ONCSD shall pay and/or reimburse INO for any amounts [*****] that is a direct result of this non-exclusive license to ONCSD.

3.2 Royalties

3.2.1 INO Royalties

3.2.1.1 For avoidance of doubt, INO does not owe ONCSD any royalty fees in exchange for the ONCSD LICENSE.

3.2.2 ONCSD Royalties

3.2.2.1 In exchange for the INO LICENSE, ONCSD shall pay to INO a royalty of [*****] on NET SALES of SECTA BUSINESS.

3.3 Currency, Payment Method.

3.3.1 All dollar amounts referred to in this AGREEMENT are United States dollars. All payments to INO under this AGREEMENT shall be made in United States dollars by check payable to “Inovio Pharmaceuticals.”

3.3.2 Amounts that are not paid when due shall accrue interest from the due date until paid, at a rate equal to [*****] per month (or maximum allowed by law, if less).

4. CONFIDENTIALITY

4.1 CONFIDENTIAL INFORMATION means and includes all technical and business information, plans, inventions, developments, discoveries, improvements, software, know-how, procedures, methods, techniques, formulae, data, processes, studies, and other proprietary ideas, whether or not patentable or copyrightable, that a party hereto identifies as confidential or proprietary at the time it is delivered or communicated to the other party hereto, or any other information that should reasonably be recognizable by its nature to be confidential or trade secret information of a party (including, without limitation, information respecting such party’s business plans, sales and sales methods, customers and prospective customers). CONFIDENTIAL INFORMATION should be in writing and marked confidential or, if oral, should be reduced to writing within two weeks of disclosure and marked confidential.

4.2 Each party shall maintain in confidence and not disclose to any third party any CONFIDENTIAL INFORMATION of the other party for the term of this AGREEMENT and for five (5) years thereafter. Each party shall ensure that its employees have access to CONFIDENTIAL INFORMATION of the other party only on a need-to-know basis, and are obligated to abide by such party’s obligations under this AGREEMENT. The foregoing obligation shall not apply to the below exceptions:

4.2.1 information that is known to the receiving party prior to the time of disclosure, and was not received directly or indirectly from the disclosing party hereunder in violation of a confidentiality obligation, unless received subject to non-disclosure and non-use obligations, or independently developed by or for the receiving party, without exposure to or benefit of the disclosing party’s CONFIDENTIAL INFORMATION, in each case, to the extent evidenced by written records;

4.2.2 information disclosed to the receiving party, without restriction, by a third party that has a right to make such disclosure;

4.2.3 information that was or becomes patented, published or otherwise part of the public domain as a result of acts by the disclosing party or a third person developing or obtaining such information as a matter of right; and

4.2.4 information which the disclosing party permits, in writing, the receiving party to publicly disclose.

4.3 If a receiving party is required to disclose any of the disclosing party’s CONFIDENTIAL INFORMATION by order of a governmental authority or a court of competent jurisdiction; the receiving party shall timely inform its disclosing party, reasonably cooperate at the disclosing parties expense with any reasonable action the disclosing party takes to attempt to obtain confidential treatment of such information by the authority or court, and limit its disclosure of such information to the extent practical.

5. TERM AND TERMINATION

5.1 This AGREEMENT, unless sooner terminated as provided in this AGREEMENT, shall terminate upon the earlier of: (a) the expiration or abandonment of the last patent that is either a patent of INO PATENT RIGHTS or ONCSD PATENT RIGHTS; or (b) twenty (20) years after the EFFECTIVE DATE.

5.2 ONCSD may terminate this AGREEMENT upon thirty (30)-days written notice to INO; and by completing all the following:

CONFIDENTIAL TREATMENT REQUESTED. OMITTED PORTIONS ARE MARKED WITH [*****] AND HAVE BEEN FILED SEPARATELY WITH THE SEC.

5.2.1 ceasing to make, have made, use, import, sell and offer for sale all products or services covered by the INO PATENT RIGHTS;

5.2.2 terminating all sublicenses relating to the INO PATENT RIGHTS, and causing all sublicensees to cease making, having made, using, importing, selling and offering for sale all products and services covered by the INO PATENT RIGHTS; and

5.2.3 paying all monies owed to INO under this AGREEMENT.

5.3 INO may terminate this AGREEMENT upon thirty (30)-days written notice to ONCSD; and by completing all the following:

5.3.1 ceasing to make, have made, use, import, sell and offer for sale all products or services covered by the ONCSD PATENT RIGHTS; and

5.3.2 terminating all sublicenses relating to the ONCSD PATENT RIGHTS, and causing all sublicensees to cease making, having made, using, importing, selling and offering for sale all products and services covered by the ONCSD PATENT RIGHTS.

5.4 ONCSD may terminate this AGREEMENT, upon ten (10)-days written notice to INO, if any of the following events of default occur:

5.4.1 INO experiences a Trigger Event (defined in Section 5.6, below);

5.4.2 INO materially breaches this AGREEMENT and does not cure the material breach within thirty (30) days after written notice of such material breach.

5.5 INO may terminate this AGREEMENT, upon ten (10)-days written notice to ONCSD, if any of the following events of default occur:

5.5.1 ONCSD is more than [*****] late in paying INO any royalties, expenses or any other monies due under this AGREEMENT and ONCSD does not immediately pay INO in full any amounts due upon written demand; or

5.5.2 ONCSD experiences a Trigger Event (defined in Section 5.6, below);

5.5.3 subject to 5.5.1, ONCSD materially breaches this AGREEMENT and does not cure the material breach within thirty (30) days after written notice of such material breach.

5.6 “Trigger Event” means any of the following:

5.6.1 If a Party:

5.6.1.1 becomes insolvent, bankrupt or generally fails to pay its material debts as such debts become due;

5.6.1.2 is adjudicated insolvent or bankrupt; admits in writing its inability to pay its debts; or shall suffer a custodian, receiver or trustee for it or substantially all of its property to be appointed and, if appointed without its consent, is not discharged within thirty (30) days of such appointment; or

5.6.1.3 makes an assignment for the benefit of creditors; or suffers proceedings under any law related to bankruptcy, insolvency, liquidation or the reorganization, readjustment or the release of debtors to be instituted against it and, if contested by it, not dismissed or stayed within thirty (30) days;

5.6.2 If proceedings under any United States law related to bankruptcy, insolvency, liquidation, or the reorganization, readjustment or the release of debtors are instituted or commenced by such Party;

5.6.3 If any order for relief is entered relating to any of the proceedings described in Section 5.6;

5.6.4 If such Party shall call a meeting of its creditors with a view to arranging a composition or adjustment of its debts; or

5.6.5 If such Party shall, by any act or failure to act, indicate its consent to, approval of or acquiescence in any of the proceedings described in Section 5.6.

5.7 Upon and after any termination of this AGREEMENT, ONCSD and any sublicensee thereof shall refrain from further manufacture, sale, marketing, importation and/or distribution of any product or service covered by the INO PATENT RIGHTS, and INO and any sublicensee thereof shall refrain from further manufacture, sale, marketing, importation and/or distribution of any product or service covered by the ONCSD PATENT RIGHTS.

5.8 Upon termination of this AGREEMENT, each (receiving) party shall, at the other (disclosing) party’s request, return to the other party all CONFIDENTIAL INFORMATION (except for one copy for archival purposes, to the extent required by law) of the other party provided hereunder.

5.9 Each party’s obligation to pay all monies owed and accruing as of the date of termination under this AGREEMENT shall survive termination of this AGREEMENT.

6. IMPROVEMENTS TO INVENTIONS

6.1 When an improvement to the INO PATENT RIGHTS is conceived or reduced to practice by ONCSD and/or its sublicensee(s), ONCSD and/or its sublicense(s) hereby assign their entire right, title and interest in such improvement to INO. Furthermore, ONCSD and/or sublicense(s) agree to cooperate with INO in obtaining patent protection to such improvement at INO’s cost, including but not limited to the execution of any and all lawful papers in the U.S. and foreign patent offices. INO hereby grants ONCSD a license in ONCSD FIELD to such improvements and under any resulting patents related to such improvement under similar terms as that provided for INO PATENT RIGHTS under this AGREEMENT.

6.2 When an improvement to the ONCSD PATENT RIGHTS is conceived or reduced to practice by INO and/or its sublicensee(s), INO and/or its sublicense(s) hereby assign their entire right, title and interest in such improvement to ONCSD. Furthermore, INO and/or sublicense(s) agree to cooperate with ONCSD in obtaining patent protection to such improvement at ONCSD’s cost, including but not limited to the execution of any and all lawful papers in the U.S. and foreign patent offices. ONCSD hereby grants INO a license in INO FIELD to such improvements and under any resulting patents related to such improvement under similar terms as that provided for ONCSD PATENT RIGHTS under this AGREEMENT.

7. INFRINGEMENT AND LITIGATION

7.1 INO and ONCSD are responsible for notifying each other promptly of any known or suspected infringement of ONCSD PATENT RIGHTS and INO PATENT RIGHTS, respectively, which may come to their attention after the EFFECTIVE DATE. INO and ONCSD shall consult one another in a timely manner concerning an appropriate response to the infringement.

7.2 ONCSD may prosecute infringement of the INO PATENT RIGHTS at its own expense. ONCSD shall not settle or compromise any such suit in a manner that imposes any obligations or restrictions on INO or grants any rights to the INO PATENT RIGHTS, without INO’s prior written permission. Financial recoveries from any such litigation will first be applied to reimburse ONCSD for its litigation expenditures with additional recoveries being paid to ONCSD, subject to lost royalty due INO based on such infringement.

7.3 INO may prosecute infringement of the ONCSD PATENT RIGHTS at its own expense. INO shall not settle or compromise any such suit in a manner that imposes any obligations or restrictions on ONCSD or grants any rights to the ONCSD PATENT RIGHTS, without ONCSD’s prior written permission. Financial recoveries from any such litigation will first be applied to reimburse INO for its litigation expenditures with additional recoveries being paid to INO, subject to lost royalty due ONCSD based on such infringement.

7.4 ONCSD’s rights under Section 7.2 are subject to the continuing right of INO to intervene at INO’s own expense and join ONCSD in any claim or suit for infringement of the INO PATENT RIGHTS. Any consideration received by INO or ONCSD in settlement of any claim or suit shall be shared between INO and ONCSD in proportion with each party’s share of the litigation expenses reasonably incurred in such infringement action.

7.5 INO’s rights under Section 7.3 are subject to the continuing right of ONCSD to intervene at ONCSD’s own expense and join INO in any claim or suit for infringement of the ONCSD PATENT RIGHTS. Any consideration received by INO or ONCSD in settlement of any claim or suit shall be shared between INO and ONCSD in proportion with each party’s share of the litigation expenses reasonably incurred in such infringement action.

7.6 If ONCSD fails to prosecute any material infringement of INO PATENT RIGHTS, INO may prosecute such material infringement at its own expense. In such event, financial recoveries will be entirely retained by INO.

7.7 If INO fails to prosecute any material infringement of ONCSD PATENT RIGHTS, ONCSD may prosecute such material infringement at its own expense. In such event, financial recoveries will be entirely retained by ONCSD.

7.8 In any action to enforce any of the INO PATENT RIGHTS, or the ONCSD PATENT RIGHTS, either party, at the request and reasonable expense of the other party, shall cooperate to the fullest extent reasonably possible. This provision shall not be construed to require either party to undertake any activities, including legal discovery, at the request of any third party, except as may be required by lawful process of a court of competent jurisdiction.

7.9 INO agrees and covenants not to xxx ONCSD for patent infringement for ONCSD’s practice in the ONCSD FIELD based on patents owned or controlled (having rights to xxx) by INO other than the INO PATENT RIGHTS provided ONCSD has not breached any of its obligations under this Agreement. However, in return, ONCSD agrees not to challenge the validity, ownership, inventorship, or other related right associated with a INO owned or licensed patent.

7.10 ONCSD agrees and covenants not to xxx INO for patent infringement for INO’s practice in the INO FIELD based on patents owned or controlled (having rights to xxx) by ONCSD other than the ONCSD PATENT RIGHTS provided INO has not breached any of its obligations under this Agreement. However, in return, INO agrees not to challenge the validity, ownership, inventorship, or other related right associated with a ONCSD owned or licensed patent.

8. REPRESENTATIONS AND WARRANTIES; DISCLAIMER OF ADDITIONAL WARRANTIES; INDEMNIFICATION

8.1 INO represents and warrants to ONCSD that to its knowledge as of the date hereof:

8.1.1 INO has the full authority to execute and deliver this AGREEMENT.

8.1.2 No material claim by any third party contesting the validity, enforceability, licensability, use or ownership of any of such INO PATENT RIGHTS has been made, is currently outstanding or is threatened against INO.

8.1.3 No loss or expiration of any part of the INO PATENT RIGHTS is currently pending.

8.2 ONCSD represents and warrants to INO that to its knowledge as of the date hereof:

8.2.1 ONCSD has the full authority to execute and deliver this AGREEMENT.

8.2.2 No material claim by any third party contesting the validity, enforceability, licensability, use or ownership of any of such ONCSD PATENT RIGHTS has been made, is currently outstanding or is threatened against ONCSD.

8.2.3 No loss or expiration of any part of the ONCSD PATENT RIGHTS is currently pending.

8.3 EXCEPT AS SET FORTH IN SECTION 8.1, ALL TECHNOLOGY LICENSED UNDER THE INO PATENT RIGHTS IN THIS AGREEMENT ARE PROVIDED ON AN “AS IS” BASIS AND INO MAKES NO REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT THERETO. BY WAY OF EXAMPLE, BUT NOT OF LIMITATION, INO MAKES NO REPRESENTATIONS OR WARRANTIES (i) OF COMMERCIAL UTILITY; (ii) OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE; OR (iii) THAT THE USE OF THE LICENSED TECHNOLOGY UNDER THIS AGREEMENT WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADE SECRET OR TRADEMARK OR OTHER PROPRIETARY RIGHTS OF OTHERS. INO SHALL NOT BE LIABLE TO ONCSD, ONCSD’S SUCCESSORS OR ASSIGNS OR ANY THIRD PARTY WITH RESPECT TO: ANY CLAIM ARISING FROM USE OF THE LICENSED TECHNOLOGY AND UNDER THIS AGREEMENT OR FROM THE MANUFACTURE, USE OR SALE OF THE LICENSED TECHNOLOGY; OR ANY CLAIM FOR LOSS OF PROFITS, LOSS OR INTERRUPTION OF BUSINESS, OR FOR INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGES OF ANY KIND.

8.4 EXCEPT AS SET FORTH IN SECTION 8.2, ALL TECHNOLOGY LICENSED UNDER THE ONCSD PATENT RIGHTS IN THIS AGREEMENT ARE PROVIDED ON AN “AS IS” BASIS AND ONCSD MAKES NO REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT THERETO. BY WAY OF EXAMPLE, BUT NOT OF LIMITATION, ONCSD MAKES NO REPRESENTATIONS OR WARRANTIES (i) OF COMMERCIAL UTILITY; (ii) OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE; OR (iii) THAT THE USE OF THE LICENSED TECHNOLOGY UNDER THIS AGREEMENT WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADE SECRET OR

TRADEMARK OR OTHER PROPRIETARY RIGHTS OF OTHERS. ONCSD SHALL NOT BE LIABLE TO INO, INO’S SUCCESSORS OR ASSIGNS OR ANY THIRD PARTY WITH RESPECT TO: ANY CLAIM ARISING FROM USE OF THE LICENSED TECHNOLOGY AND UNDER THIS AGREEMENT OR FROM THE MANUFACTURE, USE OR SALE OF THE LICENSED TECHNOLOGY; OR ANY CLAIM FOR LOSS OF PROFITS, LOSS OR INTERRUPTION OF BUSINESS, OR FOR INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGES OF ANY KIND.

8.5 Indemnity

8.5.1 ONCSD shall defend, indemnify and hold harmless INO, its trustees, officers, agents and employees (individually, an “ONCSD Indemnified Party”, and collectively, the “ONCSD Indemnified Parties”), from and against any and all liability, loss, damage, action, claim or expense suffered or incurred by the ONCSD Indemnified Parties (including attorney’s fees and expenses) (individually, a “Liability”, and collectively, the “Liabilities”) that results from or arises out of: (a) the development, use, manufacture, promotion, sale or other disposition of any technology covered by the INO PATENT RIGHTS by ONCSD, its assignees, sublicensees, vendors or other third parties; (b) any breach by ONCSD of this AGREEMENT; and (c) the enforcement by a ONCSD Indemnified Party of this Section. Without limiting the foregoing, ONCSD shall defend, indemnify and hold harmless the ONCSD Indemnified Parties from and against any Liabilities resulting from:

8.5.1.1 any product liability or other claim of any kind related to the use by a third party of a technology covered by the INO PATENT RIGHTS that was manufactured, sold or otherwise disposed by ONCSD, its assignees, sublicensees, or agents, other than such Liabilities arising from or related to the inaccuracy of any representation or warranty of INO in Section 8.1 of this AGREEMENT; and

8.5.1.2 a claim by a third party that the design, composition, manufacture, use, sale, or other disposition of any technology covered by the INO PATENT RIGHTS infringes or violates any patent, copyright, trademark or other intellectual property rights of such third party, except to the extent that any such claim may relate to the inaccuracy of any representation or warranty in Section 8.1; and

8.5.1.3 clinical trials or studies conducted by or on behalf of ONCSD and/or its sublicensees relating to the technology covered by the INO PATENT RIGHTS, including, without limitation, any claim by or on behalf of a human subject of any such clinical trial or study.

8.5.2 INO shall defend, indemnify and hold harmless ONCSD, its trustees, officers, agents and employees (individually, an “INO Indemnified Party”, and collectively, the “INO Indemnified Parties”), from and against any and all liability, loss, damage, action, claim or expense suffered or incurred by the INO Indemnified Parties (including attorney’s fees and expenses) (individually, a “Liability”, and collectively, the “Liabilities”) that results from or arises out of: (a) the development, use, manufacture, promotion, sale or other disposition of any technology covered by the ONCSD PATENT RIGHTS by INO, its assignees, sublicensees, vendors or other third parties; (b) any breach by INO of this AGREEMENT; and (c) the enforcement by a INO Indemnified Party of this Section. Without limiting the foregoing, INO shall defend, indemnify and hold harmless the INO Indemnified Parties from and against any Liabilities resulting from:

8.5.2.1 any product liability or other claim of any kind related to the use by a third party of a technology covered by the ONCSD PATENT RIGHTS that was manufactured, sold or otherwise disposed by INO, its assignees, sublicensees, or agents, other than such Liabilities arising from or related to the inaccuracy of any representation or warranty of ONCSD in Section 8.2 of this AGREEMENT; and

8.5.2.2 a claim by a third party that the design, composition, manufacture, use, sale, or other disposition of any technology covered by the ONCSD PATENT RIGHTS infringes or violates any patent, copyright, trademark or other intellectual property rights of such third party, except to the extent that any such claim may relate to the inaccuracy of any representation or warranty in Section 8.2; and

8.5.2.3 clinical trials or studies conducted by or on behalf of INO and/or its sublicensees relating to the technology covered by the ONCSD PATENT RIGHTS, including, without limitation, any claim by or on behalf of a human subject of any such clinical trial or study.

8.6 ONCSD is not permitted to settle or compromise any claim or action giving rise to Liabilities in a manner that imposes any restrictions or obligations on INO or grants any rights to the INO PATENT RIGHTS without INO’s prior written consent. If ONCSD fails or declines to assume the defense of any such claim or action within thirty (30) days after notice thereof, INO may assume the defense of such claim or action for the account and at the risk of ONCSD, and any Liabilities related thereto shall be conclusively deemed a liability of ONCSD. The indemnification rights of the parties or any other Indemnified Party contained herein are in addition to all other rights which the parties or such Indemnified Party may have at law or in equity or otherwise.

Similarly, INO is not permitted to settle or compromise any claim or action giving rise to Liabilities in a manner that imposes any restrictions or obligations on ONCSD or grants any rights to the ONCSD PATENT RIGHTS without ONCSD’s prior written consent. If INO fails or declines to assume the defense of any such claim or action within thirty (30) days after notice thereof, ONCSD may assume the defense of such claim or action for the account and at the risk of INO, and any Liabilities related thereto shall be conclusively deemed a liability of INO. The indemnification rights of the parties or any other Indemnified Party contained herein are in addition to all other rights which the parties or such Indemnified Party may have at law or in equity or otherwise.

9. USE OF INO’S NAME

9.1 ONCSD and its employees and agents shall not use, and ONCSD shall not permit its sublicensees to use, INO’s name or any adaptation thereof, or any INO seal, logotype, trademark, or service xxxx, or the name, xxxx, or logotype of any INO representative or organization in any way without the prior written consent of INO.

9.2 INO and its employees and agents shall not use, and INO shall not permit its sublicensees to use, ONCSD’s name or any adaptation thereof, or any ONCSD seal, logotype, trademark, or service xxxx, or the name, xxxx, or logotype of any ONCSD representative or organization in any way without the prior written consent of ONCSD.

10. ADDITIONAL PROVISIONS

10.1 Nothing in this AGREEMENT shall be deemed to establish a relationship of principal and agent between INO and ONCSD, or between or among any of either party’s agents or employees for any purpose whatsoever, nor shall this AGREEMENT be construed as creating any other form of legal association or arrangement which would impose liability upon one party for the act or failure to act on behalf of the other party.

10.2 Either party is not permitted to assign this AGREEMENT or any part of it to any person or entity other than its AFFILIATE, either directly or by operation of law, without the prior written consent of the other party, in its sole discretion. Any prohibited assignment of this AGREEMENT or the rights hereunder shall be null and void. No assignment relieves a party of its responsibility for the performance of any accrued obligations, which it has prior to such assignment.

10.3 A waiver by either party of a breach of any provision of this AGREEMENT will not constitute a waiver of any subsequent breach of that provision or a waiver of any breach of any other provision of this AGREEMENT.

10.4 Notices, payments, statements, reports and other communications under this AGREEMENT shall be in writing and shall be deemed to have been received as of the day after the date sent if sent by public courier (e.g., Federal Express) or by Express Mail, receipt requested, and addressed as follows:

If for INO: Inovio Pharmaceuticals, Inc.

0000 Xxxxxx Xxxxxxx West

Building 18, Xxxxx 000

Xxxx Xxxx, XX 00000

Attention: J. Xxxxxx Xxx

If for ONCSD:

OncoSec Medical Inc.
8th Floor - 000 Xxxxx Xxxxxxxx Xxxxxx
Xxxx XX 00000
Attention: Xxxxx Xxxxxxx
Fax No.: 000-000-0000

with a copy to:
Xxxxxxxx Xxxxxxxx

00000 Xxxx Xxxxx Xxxxx, Xxxxx 000

Xxx Xxxxx, XX 00000-0000

Attention: Xxxxx Xxxxxx

Fax No.: 000-000-0000

Either party may change its official address upon written notice to the other party and allow for ten (10) business days for the change to be effective.

10.5 This AGREEMENT shall be construed and governed in accordance with the laws of the Commonwealth of Pennsylvania, without giving effect to conflict of law provisions. In the event that a party to this AGREEMENT perceives the existence of a dispute with the other party concerning any right or duty provided for herein, the parties will, as soon as practicable, confer in an attempt to resolve the dispute. If the parties are unable to resolve such dispute amicably, then the parties hereby submit to the exclusive jurisdiction of and venue in the courts located in the Eastern District of the Commonwealth of Pennsylvania with respect to any and all disputes concerning the subject of this AGREEMENT.

10.6 INO and ONCSD shall not discriminate against any employee or applicant for employment because of race, color, sex, sexual or affectional preference, age, religion, national or ethnic origin, handicap, or because he or she is a disabled veteran or a veteran of the Vietnam Era.

10.7 Each party agrees that it shall comply with all prevailing laws, rules and regulations that apply to its activities or obligations under this AGREEMENT.

10.8 If any provision of this AGREEMENT shall be held to be illegal, invalid or unenforceable, then such illegality, invalidity or unenforceability shall attach only to such provision, and shall not in any manner affect or render illegal, invalid or unenforceable any other provision of this AGREEMENT, and this AGREEMENT shall be carried out as if any such illegal, invalid or unenforceable provision were not contained herein.

10.9 This AGREEMENT, including the attachments expressly referred to herein and attached, embody the entire agreement and understanding among the parties hereto and thereto and supersede all prior agreements and understandings relating to the subject matter. This AGREEMENT may not be changed, modified, extended or terminated except by written amendment executed by an authorized representative of each party.

10.10 All agreements, covenants, indemnities, obligations, rights, licenses, options, representations, and warranties set forth in this AGREEMENT or accrued prior to Termination or Expiration of this AGREEMENT will survive the execution, delivery, Termination, or Expiration of this AGREEMENT and remain in full effect, unless expressly provided otherwise herein.

[SIGNATURES BY PARTIES ON FOLLOWING PAGE]

IN WITNESS WHEREOF, the parties, intending to be legally bound, have caused this AGREEMENT to be executed by their duly-authorized representatives.

INOVIO PHARMACEUTICALS, INC.		ONCOSEC MEDICAL INCORPORATED


By: J. Xxxxxx Xxx		By: Xxxxx Xxxxxxx

Name:	/s/J. Xxxxxx Xxx	Name:	/s/Xxxxx Xxxxxxx

Title:	President and CEO	Title:	President and CEO

Date:	March 24, 2011	Date:	March 24, 0000

XXXXXXXX A

Inovio Ref #

Cntry

Type

Status

Serial No.

Filing Date

Patent No.

Issue Date

GTI-1160

CIP

GRANTED

08/46756

6-Jun-95

5702359

30-Dec-97

GTI-1160

CON

GRANTED

09/427151

25-Oct-99

6451002

17-Sep-02

GTI-1160

CON

GRANTED

10/053861

17-Jan-02

6567694

20-May-03

GTI-1160

DIV

GRANTED

09/551327

18-Apr-00

6418341

9-Jul-02

GTI-1160

XXX

GRANTED

90/005590

15-Dec-99

5702359C1

28-Mar-06

GTI-1160

PCT

GRANTED

08/930168

10-Apr-95

5810762

22-Sep-98

GTI-1160

GRANTED

08/042039

1-Apr-93

5439440

8-Aug-95

GTI-1160

CIP

GRANTED

08/537265

29-Sep-95

5993434

00-Xxx-00

XXX-0000

CON

GRANTED

10/177560

21-Jun-02

6569149

27-May-03

GTI-1160

CON

GRANTED

10/213514

6-Aug-02

6763264

13-Jul-04

GTI-1160

PCT

GRANTED

PA/A/1997/006929

10-Apr-95

218786

21-Jan-04

GTI-1160

PCT

GRANTED

PA/A/1997/008316

22-May-96

248023

13-Aug-07

GTI-1160

PCT

GRANTED

706014/97

10-Apr-95

247255

10-Dec-99

GTI-1160

PCT

GRANTED

708424/97

22-May-96

260238

0-Xxx-00

XXX-0000

PCT

GRANTED

530968/96

10-Apr-95

3338880

16-Aug-02

XXX-0000

XXX

GRANTED

02008920.7

10-Apr-95

1240917

23-Jun-04

XXX-0000

EPC

GRANTED

96916550.5

22-May-96

0874663

00-Xxx-00

XXX-0000

EDV

GRANTED

02008920.7

10-Apr-95

1240917

23-Jun-04

GTI-1160

EPC

GRANTED

96916550.5

22-May-96

0874663

29-Sep-99

GTI-1160

DIV

GRANTED

02008920.7

10-Apr-95

1240917

23-Jun-04

GTI-1160

PCT

GRANTED

96916550.5

22-May-96

0874663

29-Sep-99

XXX-0000

XXX

GRANTED

02008920.7

10-Apr-95

1240917

23-Jun-04

GTI-1160

EPC

GRANTED

96916550.5

22-May-96

69604509.5

29-Sep-99

GTI-1160

PCT

GRANTED

96194608.3

22-May-96

ZL96194608.3

26-May-04

GTI-1160

PCT

GRANTED

2216131

10-Apr-95

2216131

5-Feb-02

GTI-1160

PCT

GRANTED

2218255

22-May-96

2218255

00-Xxx-00

XXX-0000

GRANTED

98/7596

21-Aug-98

98/7596

31-Aug-99

GTI-1200

CIP

GRANTED

09/177678

22-Oct-98

6241701

5-Jun-01

GTI-1200

CON

GRANTED

09/861016

18-May-01

6516223

4-Feb-03

GTI-1200

DIV

GRANTED

09/189062

9-Nov-98

6233482

15-May-01

GTI-1200

DIV

GRANTED

09/189360

9-Nov-98

6181964

30-Jan-01

GTI-1200

DIV

GRANTED

09/189070

9-Nov-98

6068650

30-May-00

GTI-1200

GRANTED

08/905240

1-Aug-97

6055453

25-Apr-00

GTI-1200

CON

GRANTED

09/900601

5-Jul-01

7412284

12-Aug-08

GTI-1200

DIV

GRANTED

09/227417

8-Jan-99

6216034

10-Apr-01

GTI-1200

DIV

GRANTED

09/227416

8-Jan-99

6014584

11-Jan-00

GTI-1200

PCT

GRANTED

00-0000-0000000

31-Jul-98

756252

00-Xxx-00

XXX-0000

DIV

GRANTED

2002-57679

31-Jul-98

4180285

5-Sep-08

GTI-1200

PCT

GRANTED

00106147.9

31-Jul-98

1027049

28-Apr-06

GTI-1200

PCT

GRANTED

98801461.0

31-Jul-98

98801461.0

7-Sep-05

GTI-1200

CN-2

PCT

GRANTED

200510084733.9

31-Jul-98

1768873

28-Jan-11

XXX-0000

XXX

XXXXXXX

0000000

31-Jul-98

2268026

29-Jul-03

GTI-1200

PCT

GRANTED

86823/98

31-Jul-98

734343

27-Sep-01

GTI-1200

PCT

GRANTED

17074/00

21-Oct-99

767814

11-Mar-04

GTI-1200

GRANTED

P990105331

21-Oct-99

AR020932B1

30-May-06

GTI-1200

PCT

GRANTED

98938256.9

31-Jul-98

999867

08-Sep-2010

XXX-0000

XXX

XXXXXXX

00000000.0

31-Jul-98

999867

08-Sep-2010

GTI-1200

PCT

GRANTED

98938256.9

31-Jul-98

999867

08-Sep-2010

XXX-0000

PCT

GRANTED

98938256.9

31-Jul-98

999867

08-Sep-2010

GTI-1200

DIV

GRANTED

200510084733.9

31-Jul-98

1768873

28-Jan-2011

GTI-1360

CIP

GRANTED

10/339708

8-Jan-03

7171264

30-Jan-07

GTI-1360

GRANTED

09/567404

8-May-00

6520950

18-Feb-03

GTI-1250

GRANTED

6120493

19-Sep-2000

GTI-1250

CON

GRANTED

6208893

27-Mar-2001

GTI-1110

CON

GRANTED

7181271

20-Feb-2007

GTI-1230

CON

GRANTED

6865416

08-Mar-2005

GTI-1230

GRANTED

6347247

12-Feb-2002

GTI-1230

PENDING

99922830.7

07-May-1999

GTI-1250

GRANTED

6009347

28-Dec-1999

APPENDIX B

Inovio Ref #

Cntry

Type

Status

Serial No.

Filing Date

Patent No.

Issue Date

GTI-1130

PCT

Granted

49883/99

13-Jul-1999

770092

27-May-2004

GTI-1130

PCT

Published

2337652

13-Jul-1999

GTI-1130

PCT

Published

99933937.7

13-Jul-1999

GTI-1130

ORD

Granted

09/352809

13-Jul-1999

6697669

24-Feb-2004

GTI-1130

CIP

Granted

10/165657

07-Jun-2002

6678556

13-Jan-2004

GTI-1130

CON

Granted

10/756946

13-Jan-2004

7570992

04-Aug-2009

GTI-1130

CIP

Granted

09/625825

26-Jul-2000

6654636

25-Nov-2003

GTI-1130

CIP

Granted

10/233007

30-Aug-2002

6972013

06-Dec-2005

GTI-1130

CON

Published

11/291459

30-Nov-2005

GTI-1370

PCT

Granted

41771/00

23-Mar-2000

778736

14-Apr-2005

GTI-1370

PCT

Published

00921451.1

23-Mar-2000

GTI-1370

ORD

Granted

89105497

11-Apr-2000

NI-153798

06-Aug-2002

GTI-1370

DIV

Granted

10/215963

08-Aug-2002

7054685

30-May-2006

GTI-1370

ORD

Granted

09/535683

23-Mar-2000

6678558

13-Jan-2004

GTI-1530

EPC

Granted

99966432.9

17-Dec-1999

1140283

08-Mar-2006

GTI-1530

PCT

Granted

14354/95

13-Dec-1994

691237

27-Aug-1998

GTI-1530

PCT

Granted

68821/98

02-Apr-1998

741399

14-Mar-2002

GTI-1530

PCT

Granted

21969/00

17-Dec-1999

763535

06-Nov-2003

GTI-1530

PCT

Granted

2185024

13-Dec-1994

2185024

08-May-2001

GTI-1530

PCT

Published

2311474

02-Apr-1998

GTI-1530

EPC

Granted

99966432.9

17-Dec-1999

1140283

08-Mar-2006

GTI-1530

EPC

Granted

95905926.2

13-Dec-1994

P69426210.2

25-Oct-2000

GTI-1530

EPC

Granted

98914475.3

02-Apr-1998

69806794.0

24-Jul-2002

GTI-1530

EPC

Granted

99966432.9

17-Dec-1999

1140283

08-Mar-2006

GTI-1530

PCT

Granted

95905926.2

13-Dec-1994

0751802

25-Oct-2000

GTI-1530

PCT

Granted

98914475.3

02-Apr-1998

1028777

24-Jul-2002

GTI-1530

PCT

Granted

99966432.9

17-Dec-1999

1140283

08-Mar-2006

GTI-1530

EPC

Granted

99966432.9

17-Dec-1999

1140283

08-Mar-2006

GTI-1530

EPC

Granted

95905926.2

13-Dec-1994

0751802

25-Oct-2000

XXX-0000

EPC

Granted

98914475.3

02-Apr-1998

1028777

24-Jul-2002

GTI-1530

EPC

Granted

99966432.9

17-Dec-1999

1140283

08-Mar-2006

XXX-0000

EPC

Granted

95905926.2

13-Dec-1994

0751802

25-Oct-2000

XXX-0000

EPC

Granted

98914475.3

02-Apr-1998

1028777

24-Jul-2002

XXX-0000

EPC

Granted

99966432.9

17-Dec-1999

1140283

08-Mar-2006

GTI-1530

EPC

Granted

95905926.2

13-Dec-1994

0751802

25-Oct-2000

GTI-1530

EPC

Granted

99966432.9

17-Dec-1999

1140283

08-Mar-2006

GTI-1530

PCT

Granted

525651/95

13-Dec-1994

3554935

21-May-2004

XXX-0000

EPC

Granted

99966432.9

17-Dec-1999

1140283

08-Mar-2006

GTI-1530

ORD

Granted

87106879

05-May-1998

NI-108036

01-Sep-1999

GTI-1530

CIP

Granted

08/219970

30-Mar-1994

5462520

31-Oct-1995

GTI-1530

ORD

Granted

07/931061

17-Aug-1992

5318514

07-Jun-1994

GTI-1530

CIP

Granted

08/310647

22-Sep-1994

5464386

07-Nov-1995

GTI-1530

CIP

Granted

08/552200

02-Nov-1995

5688233

18-Nov-1997

GTI-1530

CIP

Granted

08/964436

04-Nov-1997

6009345

28-Dec-1999

GTI-1530

CIP

Granted

09/213782

17-Dec-1998

5968006

19-Oct-1999

GTI-1540

EPC

Granted

95925349.3

27-Jun-1995

69502733.6

27-May-1998

GTI-1540

PCT

Granted

95925349.3

27-Jun-1995

0788392

27-May-1998

XXX-0000

EPC

Granted

95925349.3

27-Jun-1995

0788392

27-May-1998

GTI-1540

CIP

Granted

08/328895

25-Oct-1994

6132419

17-Oct-2000

GTI-1540

CIP

Granted

08/304584

12-Sep-1994

5501662

26-Mar-1996

GTI-2010

PCT

Pending

PCT/US2009/000273

28-Jun-2010

GTI-2010

PCT

Pending

2710408

21-Jun-2010

GTI-2010

PCT

Pending

PCT/US2009/000273

23-Jul-2010

GTI-2010

PCT

Pending

09702445.9

16-Jan-2009

GTI-2010

PCT

Pending

4726/DELNP/2010

30-Jun-2010

GTI-2010

PCT

Pending

PCT/US2009/000273

15-Jul-2010

GTI-2010

PCT

Pending

00-0000-0000000

16-Aug-2010

GTI-2010

ORD

Pending

12836163

14-Jul-2010

GTI-2010

ORD

Published

PCT/US2009/000273

16-Jan-2009

GTI-5000

EPC

Granted

98909691.2

03-Apr-1998

1023107

30-Aug-2006

GTI-5000

PCT

Granted

69906/98

03-Apr-1998

733628

30-Aug-2001

GTI-5000

EPC

Granted

98909691.2

03-Apr-1998

1023107

30-Aug-2006

GTI-5000

PCT

Granted

2285056

03-Apr-1998

2285056

14-Dec-2004

GTI-5000

EPC

Granted

98909691.2

03-Apr-1998

1023107

30-Aug-2006

GTI-5000

PCT

Granted

98803980.X

03-Apr-1998

ZL98803980.X

24-Apr-2006

GTI-5000

EPC

Granted

98909691.2

03-Apr-1998

DE69835761.2-08

30-Aug-2006

GTI-5000

EPC

Granted

98909691.2

03-Apr-1998

1023107

30-Aug-2006

GTI-5000

PCT

Granted

199900882

03-Apr-1998

002087

24-Dec-2001

GTI-5000

PCT

Granted

98909691.2

03-Apr-1998

1023107

30-Aug-2006

GTI-5000

EPC

Granted

98909691.2

03-Apr-1998

1023107

30-Aug-2006

GTI-5000

EPC

Granted

98909691.2

03-Apr-1998

1023107

30-Aug-2006

XXX-0000

EPC

Granted

98909691.2

03-Apr-1998

1023107

30-Aug-2006

GTI-5000

EPC

Granted

98909691.2

03-Apr-1998

1023107

30-Aug-2006

GTI-5000

EPC

Granted

98909691.2

03-Apr-1998

1023107

30-Aug-2006

GTI-5000

PCT

Granted

1999-7009009

03-Apr-1998

427786

07-Apr-2004

GTI-5000

EUC

Granted

199900882

03-Apr-1998

2087

24-Dec-2001

GTI-5000

EPC

Granted

98909691.2

03-Apr-1998

1023107

30-Aug-2006

GTI-5000

PCT

Granted

999026

03-Apr-1998

253159

09-Jan-2008

XXX-0000

EPC

Granted

98909691.2

03-Apr-1998

1023107

30-Aug-2006

GTI-5000

PCT

Granted

19994820

03-Apr-1998

327806

28-Sep-2009

XXX-0000

PCT

Granted

337853

03-Apr-1998

337853

08-Jul-2002

GTI-5000

EUC

Granted

199900882

03-Apr-1998

2087

24-Dec-2001

GTI-5000

EPC

Granted

98909691.2

03-Apr-1998

1023107

30-Aug-2006

GTI-5000

CIP

Granted

09/565140

05-May-2000

6261281

17-Jul-2001

GTI-5000

ORD

Granted

09/055084

03-Apr-1998

6110161

29-Aug-2000

GTI-5000

CON

Granted

10/141561

07-May-2002

6610044

26-Aug-2003

GTI-5000

CON

Granted

10/620271

14-Jul-2003

6958060

25-Oct-2005

GTI-5000

ORD

Allowed

12/070233

15-Feb-2008

GTI-5001

DIV

Pending

2009202678

01-Jul-2009

GTI-5001

PCT

Published

2491000

04-Jul-2003

GTI-5001

PCT

Granted

03820724.9

04-Jul-2003

03820724.9

28-Apr-2010

GTI-5001

PCT

Granted

200401558

04-Jul-2003

009203

28-Dec-2007

GTI-5001

PCT

Published

03762794.0

04-Jul-2003

GTI-5001

PCT

Published

05108751.7

04-Jul-2003

GTI-5001

PCT

Pending

4137/DELNP/2004

04-Jul-2003

GTI-5001

PCT

Granted

2004-518966

04-Jul-2003

4461012

19-Feb-2010

GTI-5001

DIV

Published

2009-279074

09-Dec-2009

GTI-5001

PCT

Granted

PA/A/2005/000155

04-Jul-2003

277428

21-Jul-2010

XXX-0000

DIV

Granted

562306

04-Jul-2003

562306

08-Oct-2009

XXX-0000

DIV

Granted

566578

04-Jul-2003

566578

12-Nov-2009

GTI-5001

EUC

Granted

200401558

04-Jul-2003

9203

28-Dec-2007

GTI-5001

ORD

Granted

10/612304

03-Jul-2003

7328064

05-Feb-2008

GTI-5001

CON

Published

11/985825

00-Xxx-0000

XXX-0000

PCT

Granted

2005/0058

04-Jul-2003

2005/0058

29-Mar-2006

GTI-7001

PCT

Pending

2007215263

09-Feb-2007

GTI-7001

PCT

Published

2635437

09-Feb-2007

GTI-7001

ORD

Pending

2686855

16-May-2008

GTI-7001

PCT

Pending

200780002313.9

09-Feb-2007

GTI-7001

PCT

Published

07750450.4

09-Feb-2007

GTI-7001

ORD

Published

08767759.7

20-Nov-2009

GTI-7001

PCT

Pending

6100/DELNP/2008

11-Jul-2008

GTI-7001

PCT

Published

2008-554405

09-Feb-2007

GTI-7001

PCT

Published

7019463/2008

09-Feb-2007

GTI-7001

PCT

Pending

MX/A/2008/008981

09-Feb-2007

GTI-7001

PCT

Pending

20083811

09-Feb-2007

GTI-7001

ORD

Published

11/704591

09-Feb-2007

GTI-7001

CIP

Published

11/894653

20-Aug-2007

GTI-7001

ORD

Published

PCT/US2008/006311

16-May-2008

GTI-1220

GRANTED

6027488

22-Feb-00

GTI-1220

DIV

GRANTED

6746441

08-Jun-04

GTI-1590

ORD

GRANTED

6192270

20-Feb-01

GTI-1560

ORD

GRANTED

6150148

21-Nov-00

Inovio Ref #

Cntry

Type

Status

Publication

Filing Date

Patent No.

Issue Date

ORD

GRANTED

6528315

4-Mar-03

PCT

WO 99/01157

GRANTED

WO 99/01157

0991425

30-Sep-05

GRANTED

WO 99/01157

0991425

30-Sep-05

GRANTED

WO 99/01157

0991425

30-Sep-05

GRANTED

WO 99/01157

0991425

30-Sep-05

GRANTED

WO 99/01157

0991425

30-Sep-05

GRANTED

WO 99/01157

0991425

30-Sep-05

GRANTED

WO 99/01157

0991425

30-Sep-05

GRANTED

WO 99/01157

0991425

30-Sep-05

WO 99/01157

GRANTED

6939862

6-Sep-05

PCT

WO 99/001158

GRANTED

WO 99/001158

0991426

GRANTED

WO 99/001158

0991426

GRANTED

WO 99/001158

0991426

GRANTED

WO 99/001158

0991426

GRANTED

WO 99/001158

0991426

GRANTED

WO 99/001158

0991426

GRANTED

WO 99/001158

0991426

GRANTED

WO 99/001158

0991426

Document Metadata

Table of Contents

CONFIDENTIAL TREATMENT REQUESTED. OMITTED PORTIONS ARE MARKED WITH [*****] AND HAVE BEEN FILED SEPARATELY WITH THE SEC. CROSS-LICENSE AGREEMENT

Document Metadata